Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Raloxifene in Preventing Breast Cancer in Premenopausal Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00019500
Recruitment Status : Completed
First Posted : June 23, 2005
Last Update Posted : June 20, 2013
Sponsor:
Information provided by:
National Cancer Institute (NCI)

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of raloxifene may be an effective way to prevent breast cancer in premenopausal women.

PURPOSE: Phase II trial to study the effectiveness of raloxifene in preventing invasive breast cancer in premenopausal women.


Condition or disease Intervention/treatment Phase
Breast Cancer Drug: raloxifene Procedure: evaluation of cancer risk factors Phase 2

Detailed Description:

OBJECTIVES:

  • Determine the safety and tolerability of raloxifene in premenopausal women at high risk of developing invasive breast cancer.
  • Determine the effect of raloxifene on blood steroid hormone levels (luteinizing hormone, estradiol, progesterone) and carotenoid levels during the menstrual cycle in these participants.
  • Determine the effect of raloxifene on the endometrium and ovaries in these participants.
  • Determine the effect of raloxifene on biochemical markers of bone metabolism, lipid profiles, and fibrinogen in these participants.
  • Determine the effect of raloxifene on health-related quality of life of these participants.
  • Determine the effect of raloxifene on bone mineral density in the spine and hip of these participants.

OUTLINE: This is an open-label study.

Participants are medically evaluated, followed by an observation period of 1 to 2 menstrual cycles. After the observation period, participants receive oral raloxifene once daily for 2 years.

Quality of life is assessed 1 week prior to study drug administration and at 6, 12, 24 and 36 months after study drug administration.

Participants are followed for 1 year.

PROJECTED ACCRUAL: A total of 41 participants will be accrued for this study within 3 years.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Prevention
Official Title: A Randomized Phase II Trial of Two Doses of Raloxifene in Pre-Menopausal Women at High Risk For Developing Invasive Breast Cancer
Study Start Date : December 1998
Actual Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Raloxifene

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   23 Years to 47 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • At risk for developing invasive breast cancer by virtue of 1 of the following criteria:

    • Gail model risk equal to that of an average 60 year old woman as determined using the Gail risk assessment model
    • Lobular neoplasia
    • Atypical ductal hyperplasia with a positive family history of breast cancer
    • Ductal carcinoma in situ previously treated with mastectomy or lumpectomy and radiation
    • BRCA1 or BRCA2 mutation-positive genotyping

    • Family history consistent with hereditary cancer syndrome of increased breast cancer risk defined as 1 of the following:

      • Family with more than 2 breast cancer cases and one or more cases of ovarian cancer diagnosed at any age
      • Family with more than 3 breast cancer cases diagnosed before age 50
      • Sister pairs with 2 breast cancers, 2 ovarian cancers, or 1 breast and 1 ovarian cancer diagnosed before age 50

  • Premenopausal

    • Menstrual cycle of 26-35 days
    • No change in menstrual pattern within the past 6 months (no irregularities)
    • FSH level less than 20 mIU/mL

  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • 23 to 47

Sex

  • Female

Menopausal status

  • Premenopausal

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • No history of bleeding disorder

Hepatic

  • No history of cirrhosis of the liver
  • SGOT/SGPT no greater than 3 times upper limit of normal (ULN)

Renal

  • Creatinine no greater than 1.7 mg/dL

Cardiovascular

  • No history of pulmonary embolism or deep venous thrombosis

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile participants must use effective non-hormonal contraception (e.g. barrier methods, spermicides, or surgical methods) during and for 3 months after study
  • No history of infertility with a suspected ovarian etiology or recurrent ovarian cysts
  • No allergy to raloxifene
  • No dysfunctional uterine bleeding
  • No menorrhagia
  • No cervical dysplasia or significant uterine pathology requiring concurrent surgery
  • No medical or psychiatric disorder that would preclude study participation
  • Normal CA 125 levels

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • At least 6 months since prior steroid therapy (e.g., tamoxifen, estrogen, DHEA, anabolic steroids, or oral contraceptives)

Radiotherapy

  • See Disease Characteristics

Surgery

  • See Disease Characteristics
  • No prior hysterectomy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00019500


Locations
Layout table for location information
United States, Maryland
Medicine Branch
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Study Chair: Jennifer Eng-Wong, MD National Cancer Institute (NCI)
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:
Orzano JA, Prindiville S, Zujewski J, et al.: Mammographic density is not modulated by raloxifene in pre-menopausal women at high-risk for invasive breast cancer. [Abstract] Breast Cancer Res Treat 88 (Suppl 1): A-4035, 2004.
Eng-Wong J, Stratton P, Forman M, et al.: Effect of raloxifene on menstrual cycle length and quality of life in premenopausal women at high risk for invasive breast cancer. [Abstract] American Association for Cancer Research: Frontiers in Cancer Prevention Research, October 26 - 30, 2003, Phoenix, AZ. 12: A-193, 1300s, 2003.
Premkumar A, Stratton P, Johnson D, et al.: Long term effects of raloxifene on the ovary and uterus in pre-menopausal women at high risk for developing breast cancer. [Abstract] Ultrasound Obstet Gynecol 22 (Suppl 1): A-OC164, 44, 2003.
Eng-Wong J, Venzon D, Schmidt B, et al.: The effect of raloxifene on insulin-like growth factor-1 (IGF-1) and insuline-like growth factor binding protein-3 (IGFBP-3) in premenopausal women at high risk for developing breast cancer. [Abstract] American Association for Cancer Research: Frontiers in Cancer Prevention Research, October 14 -18, 2002, Boston, MA. 11: A-317, 1162s, 2002.
Premkumar A, Stratton P, Avila N, et al.: Raloxifene effects on the ovary and the uterus in premenopausal subjects at high risk for developing breast cancer - sonographic evaluation. [Abstract] Ultrasound Obstet Gynecol 20 (Supp 1): A-P174, 72, 2002.
Zujewski J, Eng-Wong J, Reynolds J, et al.: A phase 2 trial of raloxifene in premenopausal women at high risk for developing invasive breast cancer. [Abstract] Breast Cancer Res Treat 76 (Suppl 1): A-417, 2002.

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00019500    
Obsolete Identifiers: NCT00001700
Other Study ID Numbers: CDR0000066428
NCI-98-C-0123
MB-402
First Posted: June 23, 2005    Key Record Dates
Last Update Posted: June 20, 2013
Last Verified: April 2009
Keywords provided by National Cancer Institute (NCI):
breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Raloxifene Hydrochloride
Estrogen Antagonists
 Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents